Eli Lilly to Supply Additional Doses of COVID-19 Therapy to U.S. Government
Eli Lilly has inked an agreement with the U.S. government to supply 388,000 additional doses of its COVID-19 antibody therapy, etesevimab, to be used together with doses of the company’s bamlanivimab previously purchased by the government.
Lilly said the etesevimab doses will be shipped by the end of this year and will bring in revenue of approximately $330 million. The government resumed distributing the antibody combination earlier this month after halting shipping over concerns about the treatment’s effectiveness against coronavirus variants.
Bamlanivimab and etesevimab are authorized by the FDA for treating mild-to-moderate COVID-19 in people 12 years and older who are at high risk of progressing to severe disease, including hospitalization and death.